

EGM 2023 QUESTIONS

21ST DECEMBER 2023

	QUESTION	RESPONSE
1	Why did some directors choose to resign?	Upon the exit of Cipla Ltd, the three directors that had been nominated to the Board by Cipla Ltd resigned.
2	<p>I need to be guided on how strategic it was in terms of business growth for the disposal of majority holding and control to the new holder. What prospects are in scope and what level of expertise is the new majority holder bringing on board?</p> <p>What are the new goals for the company and how will they make the company more profitable?</p> <p>Growth plan for the next 3-5 years</p> <p>What is the implication of the change from CIPLAQCIL and back to QCIL? For Investors what does that mean? Am aware of the new shareholders who are taking over CIPLA share, but why did CIPLA depart so unceremoniously despite the rosy picture it has been giving, were they pushed out or did they jump ship?</p>	<p>QCIL's belief in the potential of Africa's pharmaceutical industry is unwavering and QCIL is committed to advancing healthcare accessibility and quality across the continent.</p> <p>With QCIL's WHO prequalification, which has recently been confirmed for another three years, and cGMP-compliant standing, an independent QCIL is better positioned to secure business from customers who recognise and value local manufacturing and the benefits associated with it, such as shorter and more reliable delivery.</p> <p>ACW SSA 3 is part of the Capitalworks Group, which has a track record of investing in growing companies. By combining ACW's expertise in investment and market dynamics and complementary relationships with QCIL's established quality manufacturing presence and reputation in the pharmaceutical landscape, QCIL expects to have additional opportunities for growth as a result of the change in control which will benefit all shareholders. QCIL's growth plans include building on its already existing strong portfolio, which will enable market expansion both locally and regionally, and will create new revenue lines for the business and enhance profitability.</p> <p>Cipla Ltd's exit from the Company was in line with Cipla Ltd's strategy to concentrate on larger markets.</p>
3	Who does a shareholder write to/address to when requesting to become a Non-Executive Director of Cipla Quality Chemical Industries Limited?	<p>Appointments to the Board are governed by the Company's Articles of Association and Governance Charter.</p> <p>Any interest in becoming a member of the Board may be addressed in writing to the Chairperson of</p>

		<p>the Nomination & Remuneration Committee through the address of the Company or email shareholder@ciplaqcil.co.ug.</p> <p>The full Company address is available on the Company Website.</p>
4	Does the change of company name to Quality Chemical Industries Limited affect any initial contracts held by the company?	The change of name of QCIL does not affect any of its rights or obligations. All contracts held by the Company will remain valid and enforceable.
5	Are shareholders allowed to apply for Cipla Jobs and what are the chances?	There exists a formal process for recruitment into any position in QCIL. A shareholder may apply for jobs in QCIL should they meet the required qualifications and will be subject to a recruitment process.
6	When will there be real attendance meeting, since the COVID ended?	This being an Extraordinary General Meeting with a short agenda, a decision was made to hold the meeting virtually. The Company will consider holding hybrid general meetings in future.
7	How are dividends sent to shareholders?	Dividends are sent to shareholders through the bank or mobile money payments. Should you wish to change the mode of payment of your dividends, please contact the Company's share registrar: SCD Registrars, located at UAP Nakawa Business Park, Block A 4 th Floor.
8	I heard about a plan of starting an oncology plant as a way of expanding the business, how true is it?	The Company regularly reviews its expansion prospects, taking into account market conditions and their impact on demand, costs and competition. The Company also considers the best application of its scarce resources and capital. With this background, oncology remains an important therapy area and the viability of investing in a dedicated facility within the QCIL compound to manufacture oncology and sickle cell products is regularly considered.
9	<p>Is QCIL involved in the supply chain of ARVs through PEPFAR to any African state?</p> <p>Does QCIL management see any business opportunities for QCIL in view of the likely interruption of supply of ARVs through PEPFAR to countries like Uganda?</p>	<p>PEPFAR currently requires its suppliers to have US FDA certification; therefore, QCIL does not supply ARVs through PEPFAR.</p> <p>QCIL and certain of its products have the requisite certifications and prequalifications from the World Health Organization to supply the Global Fund and has done so for over ten years.</p>

		<p>At QCIL, we aim to enhance access to treatment for HIV/AIDS and other diseases. In case of any shortage in the market of medicines we manufacture, we have often supplied critical medicines on short notice. This remains an important capability in our mission to save lives.</p>
--	--	---